AnalytiXIN invites life sciences stakeholders across Indiana to a virtual Spotlight Series session introducing Provena Consortium, the newly rebranded name for Indiana’s Life Sciences Health Data Asset.
Provena Consortium is a consent-based clinical and genomic data consortium built through a partnership between Indiana University, IU Health, Eli Lilly and Company, and the Indiana Health Information Exchange. With more than 90,000 participants consented and a goal of reaching 250,000 by early 2029, Provena Consortium is positioning Indiana to host one of the largest deeply characterized, consent-based health data assets in the country — combining whole-genome sequencing, decades of longitudinal clinical depth, and the ability to recontact participants for future research and clinical trial opportunities.
Speakers
- Darshan Shah, EVP, Data and AnalytiXIN, CEOs of Indiana Corporate Partnership
- Yunlong Liu, PhD, Professor of Medical and Molecular Genetics, Indiana University School of Medicine
- Brooke Patz, Senior Project Manager, Indiana Biobank
- Tim Ryan, Vice President of Outcomes Research, Diabetes, Obesity, and Complications Research, Eli Lilly and Company
During this session, you’ll hear directly from the partners building Provena Consortium on:
- A live look at the research portal and how institutions and industry can engage with it
- How Provena Consortium is already accelerating trial enrollment, precision medicine, and cross-institutional research
- What’s ahead as Provena Consortium scales toward its 2029 goals
This session is presented in partnership with BioCrossroads and is especially relevant for life sciences researchers, industry partners, and health system leaders across Indiana.